By Dr. Vimal T. George, MD, MSc | Reviewed by CME Travel Academy Faculty
6 min read · Reviewed November 2026
On November 3, 2026, the American Thoracic Society published an official clinical practice guideline on as-needed inhaled corticosteroids in asthma in the American Journal of Respiratory and Critical Care Medicine. The message for primary care is direct: for patients 12 and older, the rescue inhaler should contain an inhaled corticosteroid. Albuterol alone is no longer the default reliever the panel wants to see. This post summarizes what the ATS recommends at each treatment step, why the panel moved away from SABA-only care, and how family medicine and internal medicine clinicians can put it to work this week. Asthma is also on day one of our Las Vegas CME conference, where primary care CME for physicians, NPs, and PAs leaves your afternoons free.
What the ATS Guideline Covers
The task force, led by Sandhya Khurana, built the guideline on six PICO questions, a systematic review with GRADE appraisal, and 79 source documents, with a literature search that ended in March 2024. Patients and a methodologist took part, and funding and conflicts of interest are disclosed. The question is narrow and practical: in adolescents and adults, should the reliever contain an inhaled corticosteroid (ICS), either as budesonide-formoterol or as an ICS plus a SABA in a combination or separate inhalers? The panel framed its answers around the familiar NAEPP treatment steps, so the recommendations map directly onto how most primary care clinicians already think about asthma. A clear summary of the recommendations is available from Guideline Central.
Steps 1 and 2: Mild Asthma
For patients 12 and older with intermittent or mild persistent asthma, the panel made four recommendations. Two are strong and two are conditional:
- Strong: use as-needed ICS-SABA rather than as-needed SABA alone.
- Strong: use as-needed ICS-formoterol rather than as-needed SABA alone.
- Conditional: use as-needed ICS plus SABA, in one inhaler or two, rather than scheduled daily ICS with as-needed SABA.
- Conditional: use as-needed ICS-formoterol rather than scheduled daily ICS with as-needed SABA.
The practical reading is that a patient with mild asthma no longer needs a daily controller to be treated properly, and that the old pairing of a SABA with a controller the patient forgets to take is the arrangement the panel ranks lowest. The conditional grades reflect lower certainty in the evidence, so shared decision-making still matters. Some patients will prefer a daily inhaler, and that remains reasonable.
Steps 3 to 5: Moderate to Severe Asthma
For patients already on a scheduled controller, the panel made a strong recommendation for maintenance-and-reliever therapy (MART) with ICS-formoterol over scheduled ICS-LABA plus as-needed SABA. With MART, one inhaler provides both the daily dose and the rescue doses, so every symptomatic puff also adds anti-inflammatory therapy. For patients who stay on a scheduled ICS-LABA, the panel conditionally suggests an ICS plus SABA reliever rather than a SABA alone, in a combination or separate inhaler. In short, the reliever should treat inflammation at every step of the ladder.
Conference Spotlight: Asthma and More at Caesars Palace
Asthma opens day one of our Las Vegas CME conference (Caesars Palace, December 18-19, 2026 or April 2-3, 2027), alongside hypertension, CKD, COPD, chronic coronary disease, and dementia. You earn 12 AMA PRA Category 1 Credits including 1 hour of Ethics in two morning sessions, with afternoons free. Registration is $995, with military and resident discounts. Prefer New Orleans on February 19-20, 2027? See the New Orleans conference. Staying home? CME Live: Your Location delivers the same credits by livestream.
✓ 12 CME hours including 1 hour of Ethics
✓ Hot breakfast both mornings and session recordings
✓ 12-month spaced-repetition curriculum and one-page point-of-care references
Why the Panel Moved Away from SABA-Only Care
The panel described its reasoning in plain terms. ICS-containing reliever therapy has been shown to improve outcomes compared with SABA alone, yet it remains underused. The panel placed the highest value on preventing severe exacerbations, and it weighed the risk of SABA-only treatment against the cumulative exposure to ICS and systemic corticosteroids. A SABA relieves bronchospasm but does nothing for the airway inflammation that drives exacerbations, and a patient who leans on albuterol alone can feel well while risk builds. An ICS-containing reliever adds treatment at exactly the moment the airway is signaling trouble. These recommendations also fit the direction of the GINA strategy, which has favored ICS-formoterol as a reliever for several years.
Putting It Into Practice
- Audit your SABA-only patients first. Anyone using albuterol more than twice a week, or with a recent oral steroid burst, is a candidate to switch today.
- Pick the product that fits the step. Budesonide-formoterol serves the as-needed and MART options. An albuterol-budesonide combination or two separate inhalers serves the ICS plus SABA options. Do not use a LABA that lacks formoterol’s rapid onset as a rescue drug.
- Teach the new technique. Patients need to know that the controller and reliever may now be the same inhaler, how many puffs per episode, and the daily maximum on the product label and in GINA.
- Check coverage and labeling. Formulary rules and FDA labels may lag the guideline, so document your reasoning and your prior authorization plan.
- Update the asthma action plan. Rewrite the written plan so green, yellow, and red zones reflect the new reliever.
Practice Pearls: Asthma Reliever FAQ
What does the ATS recommend for mild asthma?
For patients 12 and older at NAEPP Steps 1 and 2, the ATS strongly recommends an as-needed ICS-SABA or as-needed ICS-formoterol reliever over a SABA alone.
What is MART and when does the ATS recommend it?
MART is maintenance-and-reliever therapy with a single ICS-formoterol inhaler used daily and as needed. The ATS strongly recommends it at Steps 3 to 5 over scheduled ICS-LABA plus a SABA reliever.
Do all patients need to stop using albuterol?
No. The panel suggests adding an ICS to the reliever, either in a combination inhaler or alongside a SABA. The recommendation targets SABA-only reliever therapy, not the use of albuterol itself.
How certain is the evidence behind these recommendations?
The strong recommendations rest on moderate-certainty evidence, while the conditional suggestions rest on low-certainty evidence, so individual preference and cost remain part of the decision.
Bring It Back to Your Practice
The new ATS guideline gives primary care a clean rule: make the reliever treat the inflammation. If you want the full asthma update with case-based teaching, join us at our December 2026 CME in Las Vegas, the February 2027 CME in New Orleans, or the April 2027 CME in Las Vegas. Think of it as a CME vacation: two focused mornings, then the rest of the day is yours, and the same faculty livestream via CME Live: Your Location. Our Disney World conference returns July 30-31, 2027 for CME travel with the family. Clinics can book group CME for your practice, and the online course library covers primary care CME at your own pace. For related reading, see our posts on GOLD 2026 COPD guidelines and depression in primary care.

